{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:13:47Z","timestamp":1795180427252,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP20nk0101602"],"award-info":[{"award-number":["JP20nk0101602"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP20nk0101602"],"award-info":[{"award-number":["JP20nk0101602"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP20nk0101602"],"award-info":[{"award-number":["JP20nk0101602"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"the Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP20nk0101602"],"award-info":[{"award-number":["JP20nk0101602"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of this study is to understand adaptive immunity to SARS-CoV-2 through the analysis of B cell epitope and neutralizing activity in coronavirus disease 2019 (COVID-19) patients. We obtained serum from forty-three COVID-19 patients from patients in the intensive care unit of Osaka University Hospital (n\u2009=\u200912) and in Osaka City Juso Hospital (n\u2009=\u200931). Most individuals revealed neutralizing activity against SARS-CoV-2 assessed by a pseudotype virus-neutralizing assay.\nThe antibody production against the spike glycoprotein (S protein) or receptor-binding domain (RBD) of SARS-CoV-2 was elevated, with large individual differences, as assessed by ELISA. We observed the correlation between neutralizing antibody titer and IgG, but not IgM, antibody titer of COVID-19 patients. In the analysis of the predicted the linear B cell epitopes, hot spots in the N-terminal domain of the S protein were observed in the serum from patients in the intensive care unit of Osaka University Hospital. Overall, the analysis of antibody production and B cell epitopes of the S protein from patient serum may provide a novel target for the vaccine development against SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41598-021-85202-9","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T07:03:41Z","timestamp":1615791821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals"],"prefix":"10.1038","volume":"11","author":[{"given":"Shota","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Tomono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Arase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"85202_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473 (2020).","journal-title":"Lancet"},{"key":"85202_CR2","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3389\/fphar.2020.01258","volume":"11","author":"RP Saha","year":"2020","unstructured":"Saha, R. P. et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front. Pharmacol. 11, 1258 (2020).","journal-title":"Front. Pharmacol."},{"key":"85202_CR3","first-page":"4016","volume":"24","author":"C Chakraborty","year":"2020","unstructured":"Chakraborty, C., Sharma, A. R., Sharma, G., Bhattacharya, M. & Lee, S. S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur. Rev. Med. Pharmacol. Sci. 24, 4016\u20134026 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"85202_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395, 565\u2013574 (2020).","journal-title":"The Lancet"},{"key":"85202_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF-W Chan","year":"2020","unstructured":"Chan, J.F.-W. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 395, 514\u2013523 (2020).","journal-title":"The Lancet"},{"key":"85202_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"85202_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tim.2015.06.003","volume":"23","author":"G Lu","year":"2015","unstructured":"Lu, G., Wang, Q. & Gao, G. F. Bat-to-human: spike features determining \u201chost jump\u201d of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 23, 468\u2013478 (2015).","journal-title":"Trends Microbiol."},{"key":"85202_CR8","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"85202_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280 e278 (2020).","journal-title":"Cell"},{"key":"85202_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","volume":"52","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910\u2013941 (2020).","journal-title":"Immunity"},{"key":"85202_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du, L. et al. The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"85202_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"85202_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"85202_CR14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489-1501 e1415 (2020).","journal-title":"Cell"},{"key":"85202_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41564-020-00824-5","volume":"6","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat. Microbiol. 6, 51\u201358 (2021).","journal-title":"Nat. Microbiol."},{"key":"85202_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971-977 e973 (2020).","journal-title":"Immunity"},{"key":"85202_CR17","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.xcrm.2020.100126","volume":"1","author":"J Prevost","year":"2020","unstructured":"Prevost, J. et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell. Rep. Med. 1, 100126 (2020).","journal-title":"Cell. Rep. Med."},{"key":"85202_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/jcp.2005.029868","volume":"59","author":"SC Chow","year":"2006","unstructured":"Chow, S. C. et al. Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. J. Clin. Pathol. 59, 468\u2013476 (2006).","journal-title":"J. Clin. Pathol."},{"key":"85202_CR19","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","volume":"71","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 71, 2027\u20132034 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"85202_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"85202_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/v12030254","author":"SF Ahmed","year":"2020","unstructured":"Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses https:\/\/doi.org\/10.3390\/v12030254 (2020).","journal-title":"Viruses"},{"key":"85202_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/jmv.25698","volume":"92","author":"V Baruah","year":"2020","unstructured":"Baruah, V. & Bose, S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J. Med. Virol. 92, 495\u2013500 (2020).","journal-title":"J. Med. Virol."},{"key":"85202_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/jmv.25736","volume":"92","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya, M. et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J. Med. Virol. 92, 618\u2013631 (2020).","journal-title":"J. Med. Virol."},{"key":"85202_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell. Host Microbe 27, 671-680 e672 (2020).","journal-title":"Cell. Host Microbe"},{"key":"85202_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41423-020-0385-z","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng, M. & Song, L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell. Mol. Immunol. 17, 536\u2013538 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"85202_CR26","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.imu.2020.100394","volume":"20","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya, M. et al. A SARS-CoV-2 vaccine candidate: in-silico cloning and validation. Inform. Med. Unlocked 20, 100394 (2020).","journal-title":"Inform. Med. Unlocked"},{"key":"85202_CR27","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.meegid.2020.104587","volume":"85","author":"M Bhattacharya","year":"2020","unstructured":"Bhattacharya, M. et al. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4\/MD-2 complex. Infect. Genet. Evol. 85, 104587 (2020).","journal-title":"Infect. Genet. Evol."},{"key":"85202_CR28","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/jmv.25997","volume":"92","author":"C Chakraborty","year":"2020","unstructured":"Chakraborty, C. et al. Consider TLR5 for new therapeutic development against COVID-19. J. Med. Virol. 92, 2314\u20132315 (2020).","journal-title":"J. Med. Virol."},{"key":"85202_CR29","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/jmv.26078","volume":"92","author":"C Chakraborty","year":"2020","unstructured":"Chakraborty, C. et al. COVID-19: consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J. Med. Virol. 92, 2260\u20132262 (2020).","journal-title":"J. Med. Virol."},{"key":"85202_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science https:\/\/doi.org\/10.1126\/science.abc6952 (2020).","journal-title":"Science"},{"key":"85202_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/imr.12367","volume":"268","author":"A Taylor","year":"2015","unstructured":"Taylor, A. et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol. Rev. 268, 340\u2013364 (2015).","journal-title":"Immunol. Rev."},{"key":"85202_CR32","doi-asserted-by":"crossref","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4 (2019).","DOI":"10.1172\/jci.insight.123158"},{"key":"85202_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"85202_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713-721 e719 (2020).","journal-title":"Cell"},{"key":"85202_CR35","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1128\/JVI.00608-07","volume":"81","author":"H Tani","year":"2007","unstructured":"Tani, H. et al. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J. Virol. 81, 8601\u20138612 (2007).","journal-title":"J. Virol."},{"key":"85202_CR36","first-page":"272","volume":"2","author":"H Tani","year":"2011","unstructured":"Tani, H., Morikawa, S. & Matsuura, Y. Development and applications of VSV vectors based on cell tropism. Front. Microbiol. 2, 272 (2011).","journal-title":"Front. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85202-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:25:10Z","timestamp":1670027110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85202"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85202-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.22.212761","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"29 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Department of Health Development and Medicine is endowed department supported by Anges, Daicel, and Funpep. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5934"}}